

# Charles E. Stoopack M.D. FACOG

Phone: 760-845-1692 • Fax: 760-944-1333 • E-Mail: cstoopack@ucsd.edu

## Education

M.D. New York Medical College, Valhalla, N.Y., 1980

Michaelin Scholarship Recipient  
Alpha Omega Alpha Honor Society – top 15% of class

B.S. Cornell University, Ithaca, N.Y., Graduation with Distinction, 1976  
New York State Regents Scholarship recipient

## Postgraduate Training

- Internship and Residency: 1980-1984  
University of California, San Diego Dept. of Reproductive Medicine

## Board Certification

- American Board of Obstetrics and Gynecology 1987
- Recertified Annually 2023

## License

- California Medical License: G45525

## Fellowship

- Fellow and Diplomat: American College of OB/GYN

## Publications

- Tri City Medical Center, Cancer Program Annual Report 1993  
Cervical Carcinoma
- Tri City Medical Center, Cancer Program Annual Report 1990  
Endometrial Carcinoma

## Hospital Appointments

- Tri City Medical Center, Chairman, Dept. OB/GYN 2003-2004
- Tri City Medical Center, Chairman, Dept. OB/GYN 1998-2000

## OB/GYN Quality Assurance Committee

- Tri City Medical Center, Chairman, Dept. OB/GYN 1988-1989

**Academic Appointments**

- Assistant Professor/Health Sciences Clinical Instructor 2011-Present  
UC San Diego School of Medicine

Voluntary Clinical Instructor 2009- 2011  
UC San Diego

**Private Practice**

- North Coast Women's Care Medical Group, Inc. 1992-2008  
CEO and President
- Stoopack and Fenton, AGP 1989-1992  
CEO and President

**Board Positions**

- Medvec International GmbH 2006 - Present  
Chief Medical Officer

**Recognitions**

- The Award for Excellence in Teaching 2018  
UC San Diego School of Medicine
- Excellence in Teaching Award Nominee 2012, 2015  
UC San Diego School of Medicine
- Top Doctors of San Diego County 2004  
San Diego Magazine (selected by peers) 1999
- Guide to Top Doctors  
Center for the Study of Services (selected by peers)

**Research Experience**

Please see attached



**UC San Diego**  
SCHOOL OF MEDICINE

The Award for Excellence in Teaching

**Dr. Charles Stoopack**

Hereby recognized for excellence in teaching and mentoring medical students.

A handwritten signature in black ink, appearing to read "Payton Ottum".

Payton Ottum  
Teaching Award Representative  
UC San Diego School of Medicine

A handwritten signature in black ink, appearing to read "Kevin Yei".

Kevin Yei  
Class President, Class of 2021  
UC San Diego School of Medicine

**NORTH COAST WOMEN'S CARE RESEARCH**  
**FACILITY EXPERIENCE**

**Jan 2007-2012**

**Clinical Study Protocol #511.84**

A Twelve Month, Open-label, Safety Trial of XXX 50 milligrams to 100 milligrams Daily in Women with Hypoactive Sexual Desire Disorder

Principal Investigator: Douglas K. Fenton, MD

Subinvestigators: Christine Z. Brody, MD  
Charles E. Stoopack, MD  
Ross M. Langley, MD  
Lynne Calkins CRNP  
Rumiko Harkness CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 15 patients

Screened: 28

Enrolled: 28

**Jan 2007-2012**

**Clinical Study Protocol #108933 HPV 010**

A Phase IIIb, Observer-blind, Randomized, Multicenter Study with Two Parallel Groups to Compare the Immunogenicity of XXX Vaccine versus Merck's Gardasil Vaccine when administered Intramuscularly According to a 3-dose Schedule in Healthy Females 18-45 years of age.

Principal Investigator: Douglas K. Fenton, MD

Subinvestigators: Christine Z. Brody, MD  
Charles E. Stoopack, MD  
Ross M. Langley, MD  
Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN MN

Target Enrollment: 75 patients

Screened: 40 patients

Enrolled: 40 patients

**Dec. 2006-Apr. 2007****Clinical Study Protocol #FENHYDPAI4003**

A Multicenter, Double-blind, Randomized, Placebo-controlled, Multiple-dose, Parallel Group Study to Determine Time of Onset of Pain Relief Using Standard Regimen of Morphine via Intravenous PCA following Total Abdominal Hysterectomy

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 5 patients

Screened: 6 patients

Enrolled: 5 patients

**Dec 2006-Feb. 2008****Clinical Study Protocol #DR-ASC-201**

A Prospective, Multicenter, Double-blind, Randomized, Study to Evaluate Bleeding Patterns in Women Using One of Three Different Ascending EE Dose Extended-Cycle (91-Day) Oral Contraceptive Regimens (XXX) Compared to Seasonale Oral Contraceptive Regimen

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Shambra Rodriguez MA

Target Enrollment: 15 patients

Screened: 15 patients

Enrolled: 10 patients

**July 2006-present Clinical Study Protocol #511.70**

A Twenty-Four week, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of X mg of XXX twice daily and X mg once and twice daily in Premenopausal Women with Hypoactive Sexual Desire Disorder in North America

Principal Investigator: Charles E. Stoopack, MD

Subinvestigators: Christine Z. Brody, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Rumiko Harkness CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 18 patients

Screened: 36 patients

Enrolled: 36 patients

**July 2006-July 2007 Clinical Study Protocol #DR-DZL-201**

A Phase 2, Multicenter, Double-blinded, Randomized, Placebo-controlled Study to Evaluate Two Doses of XXX Vaginal Ring for the Management of Moderate to Severe Endometriosis-Related Non-menstrual Pelvic Pain

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 3 patients\* (\*Sponsor closed study prematurely)

Screened: 16 patients

Enrolled: 1 patient

**July-December 2006 Clinical Study Protocol# 3142A2-203-WW**

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of X mg and X mg Doses of XXX on the Reduction of Symptoms Associated with Endometriosis during Treatment and

**Post-Treatment in Reproductive-Aged Women**

Principal Investigator: Christine Z. Brody, MD  
 Subinvestigators: Charles E. Stoopack, MD  
 Douglas K. Fenton, MD  
 Ross M. Langley, MD  
 Lynne Calkins CRNP  
 Study Coordinator: Mary K. Fenton, RN, MN  
 Target Enrollment: 3 patients  
 Screened: 5 patients  
 Enrolled: 3 patients\* (\*Sponsor closed study prematurely)

**April 2006-Dec 2006 Clinical Study Protocol #1VIT06011**

Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation XXX versus Oral Iron in Subjects who Display Postpartum Anemia

Principal Investigator: Christine Z. Brody, MD  
 Subinvestigators: Charles E. Stoopack, MD  
 Douglas K. Fenton, MD  
 Ross M. Langley, MD  
 Lynne Calkins CRNP  
 Study Coordinator: Mary K. Fenton, RN, MN  
 Target Enrollment: 10 patients  
 Screened: 22 patients  
 Enrolled: 14 patients

**March 2006-Nov. 2007 Clinical Study Protocol #3115A1-304-WW**

A Double-Blind, Randomized, Placebo and Active Controlled Efficacy and Safety Study of XXX for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women

Principal Investigator: Douglas K. Fenton, MD  
 Subinvestigators: Christine Z. Brody, MD  
 Charles E. Stoopack, MD  
 Ross M. Langley, MD  
 Lynne Calkins CRNP  
 Study Coordinator: Mary K. Fenton, RN MN  
 Target Enrollment: 10 patients  
 Enrolled: 20 patients

Oct-Dec 2005

**Clinical Study Protocol #DOV-075-024**

A Multi-center, Double-blinded, Placebo-controlled, Randomized Study of  
XXX for the Treatment of Post-operative Pain Following Vaginal  
Hysterectomy

Principal Investigator: Charles E. Stoopack, MD

Subinvestigators: Christine Z. Brody, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MD

Target Enrollment: 8 patients

Screened: 4 patients

Enrolled: \*2 patients (\*Sponsor closed study prematurely)

May 2005-Feb 2006

**Clinical Study Protocol #1VIT03001**

Comparison of the Safety and Efficacy of a Unique Intravenous Iron  
Preparation (XXX) versus Oral Iron in Subjects Who Display  
Postpartum Anemia

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 10 patients

Screened: 13 patients

Enrolled: \*7 patients (\*Add-on Site)

May-Sept 2005

**Clinical Study Protocol #1VIT04003**

Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation  
(XXX) versus Oral Iron in the Treatment of Iron Deficiency Anemia Secondary  
to Heavy Uterine Bleeding

Principal Investigator: Christine Z. Brody, MD



Subinvestigators: Charles E. Stoopack, MD  
Douglas K. Fenton, MD  
Ross M. Langley, MD  
Lynne Calkins CRNP

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 10 patients  
Screened: 22 patients  
Enrolled: 10 patients

**May 2004 – April 2005 Clinical Study Protocol # CAPSS 320**

Comparison of the Safety and Efficacy of Patient Controlled Analgesia

Delivered by XXX versus Morphine IV Pump for Pain Management

After Non-emergent Abdominal Surgery

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD  
Douglas K. Fenton, MD  
Ross M. Langley, MD  
Darcey B. Perlman, MD

Study Coordinator: Mary K. Fenton, RN, MN

Target Enrollment: 12 patients  
Screened: 59 patients  
Enrolled: 48 patients

**May-Aug 2004 Clinical Study Protocol #11658-001**

A Prospective Evaluation of the Burden of Post-Operative Ileus and Opioid Bowel Dysfunction in Patients Undergoing Abdominal Surgery

Principal Investigator: Douglas K. Fenton, MD

Subinvestigators: Christine Z. Brody, MD  
Charles E. Stoopack, MD  
Ross M. Langley, MD  
Darcey B. Perlman, MD

Study Coordinator: Mary K. Fenton, RN MN

Target Enrollment: 8 patients  
Screened: 8 patients  
Enrolled: 8 patients

**2004 Clinical Study Protocol #BT0300C1-300-USA**  
Comparison Study of the Safety and Efficacy of a Single Dose of XXX  
versus a Single Dose of XXX in the Treatment of Vaginal Candidiasis

Principal Investigator: Christine Z. Brody, MD  
Subinvestigators: Charles E. Stoopack, MD  
Douglas K. Fenton, MD  
Ross M. Langley, MD  
Darcey B. Perlman, MD

**2004 Clinical Study Protocol #2004031**  
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group,  
Multicenter, 52 week study to evaluate the efficacy and safety of  
XXX in menopausal women with low libido not receiving systemic  
estrogen or estrogen progestin therapy

Subinvestigators: Christine Z. Brody, MD  
Charles E. Stoopack, MD  
Douglas K. Fenton, MD  
Ross M. Langley, MD  
Darcey B. Perlman, MD

**2003-2004 Clinical Study Protocol #CFAM810A US07**  
An Open Label, Single-Arm Multicenter study to evaluate the safety and  
efficacy of XXX in the episodic treatment of Recurrent Genital Herpes,  
XXX for 5 days, and in the suppressive treatment of Recurrent Genital  
Herpes, XXX for 6 months

Principal Investigator: Charles E. Stoopack, MD  
Subinvestigators: Christine Z. Brody, MD  
Douglas K. Fenton, MD  
Ross M. Langley, MD  
Darcey B. Perlman, MD  
Study Coordinator: Mary K. Fenton, RN, MN

**2002- 2003    Clinical Study Protocol #OXY-MD-10-000**

A Double-blind, Placebo and Comparator Controlled, Single-Dose

Parallel Study of the analgesic efficacy and safety of XXX in female

patients with moderate to severe post-abdominal or pelvic surgical pain

Principal Investigator:        Christine Z. Brody, MD

Subinvestigators:        Charles E. Stoopack, MD

                                 Douglas K. Fenton, MD

                                 Ross M. Langley, MD

**2002            Clinical Study Protocol #2002005**

A Phase III, Multi-national, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to evaluate the efficacy and safety of XXX for 24 weeks and safety for a further 28 weeks in naturally menopausal women with Hypoactive Sexual Disorder on concurrent oral hormone replacement therapy

Subinvestigators:        Christine Z. Brody, MD

                                 Charles E. Stoopack, MD

                                 Douglas K. Fenton, MD

                                 Ross M. Langley, MD

                                 Darcey B. Perlman, MD

**2002            Clinical Study Protocol # 2001134**

A Phase III, Multi-national, Randomized, Double-Blind, Parallel Group Placebo-controlled 24 week study to evaluate the safety and efficacy of XXX in women with hypoactive sexual desire disorder on concurrent estrogen replacement therapy who have undergone hysterectomy and bilateral oophorectomy

Subinvestigators:        Christine Z. Brody, MD

                                 Charles E. Stoopack, MD

                                 Douglas K. Fenton, MD

                                 Ross M. Langley, MD

                                 Darcey B. Perlman, MD

**2001-2003**

**Clinical Study Protocol #14CL306**

A Multicenter Phase III, Double-blind, Placebo Controlled Study of XXX in Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus in subjects undergoing Total Abdominal Hysterectomy

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD

**2000-2002**

**Clinical Study Protocol #14CL302**

A Multicenter Phase III, Double-blind, Placebo Controlled Study of XXX in Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus

Principal Investigator: Christine Z. Brody, MD

Subinvestigators: Charles E. Stoopack, MD

Douglas K. Fenton, MD

Ross M. Langley, MD